Arrowhead Pharmaceuticals (ARWR) total debt

Total debt · fiscal 2026
$1.00B

Arrowhead Pharmaceuticals (ARWR) carried total debt of $1.00B at the end of fiscal 2026 (September 30, 2026). That is 173.1% higher than the $366.28M of fiscal 2025. Figures as of 18 Nov 2026, 05:54 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Total debt, fiscal 2026
$1.00B
Change on fiscal 2025
+173.1%
Highest on record
$1.00Bfiscal 2026
Lowest on record
$115.17Mfiscal 2023
Fiscal years on record
42023–2026

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

Arrowhead Pharmaceuticals total debt, in more detail

Across the 4 fiscal years on record (2023–2026), the highest was $1.00B in fiscal 2026 and the lowest $115.17M in fiscal 2023.

Total debt was 19.9× shareholders' equity at the end of fiscal 2026.

History · 4 fiscal years

Total debt by fiscal year

Arrowhead Pharmaceuticals total debt, year by year

Arrowhead Pharmaceuticals (ARWR) total debt by fiscal year
Fiscal yearTotal debtChangeYear endedDebt ÷ equity
2026$1.00B 173.1% up19.9×
2025$366.28M 28.3% down0.8×
2024$510.55M 343.3% up2.8×
2023$115.17M—0.4×

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Total debt adds the short-term and long-term borrowings on the balance sheet at the fiscal year-end; debt-to-equity divides it by shareholders' equity and is left blank when equity is negative.

How to read it

Debt magnifies results in both directions — set it against cash, equity and the profit available to pay the interest rather than reading it alone.

Total debt at health care companies of similar size

Total debt of Arrowhead Pharmaceuticals and comparable companies
CompanyTotal debtFiscal year
Axsome Therapeutics AXSM$218.11M2025
Chemed CHE$143.76M2025
Oruka Therapeutics ORKA$1.93M2025
Arrowhead Pharmaceuticals ARWR$1.00B2026
MSA Safety MSA$627.09M2025
CG Oncology CGON$7.02M2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on ARWR

Arrowhead Pharmaceuticals, figure by figure

Arrowhead Pharmaceuticals (ARWR) overview: price, valuation and scorecardAll health care companies by market value

Arrowhead Pharmaceuticals total debt: questions and answers

How much debt does Arrowhead Pharmaceuticals have?

Arrowhead Pharmaceuticals (ARWR) carried total debt of $1.00B at the end of fiscal 2026 (September 30, 2026). That is 173.1% higher than the $366.28M of fiscal 2025.

What are the highest and lowest total debt figures on record for Arrowhead Pharmaceuticals?

Across the 4 fiscal years on record (2023–2026), the highest was $1.00B in fiscal 2026 and the lowest $115.17M in fiscal 2023.

How does Arrowhead Pharmaceuticals's debt compare with its equity?

Total debt was 19.9× shareholders' equity at the end of fiscal 2026.

How is Arrowhead Pharmaceuticals's total debt calculated?

Total debt adds the short-term and long-term borrowings on the balance sheet at the fiscal year-end; debt-to-equity divides it by shareholders' equity and is left blank when equity is negative.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Arrowhead Pharmaceuticals (ARWR) total debt”, data as of 18 November 2026. https://funkfolio.com/stock/ARWR/total-debt

Underlying data: the company's filings with the SEC and Yahoo Finance.